Nyxoah’s (NYXH) Buy Rating Reiterated at HC Wainwright

Nyxoah (NASDAQ:NYXH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Friday, Marketbeat reports. They presently have a $17.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 112.50% from the stock’s previous close.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Nyxoah in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $17.00.

Nyxoah Price Performance

Shares of NASDAQ:NYXH opened at $8.00 on Friday. The business has a fifty day moving average price of $8.86 and a 200-day moving average price of $8.53. The company has a market capitalization of $199.52 million, a PE ratio of -4.28 and a beta of 1.35. Nyxoah has a 1-year low of $4.00 and a 1-year high of $20.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

Hedge Funds Weigh In On Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Kovack Advisors Inc. purchased a new position in Nyxoah S.A. (NASDAQ:NYXH) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $96,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.